Jens Siveke
Affiliations: | Max Planck Institut for Medical Research/Technical University of Munich | ||
| Deutsches Krebsforschungszentrum (DKFZ), Germany | |||
| University of Duisburg-Essen |
Website:
https://dktk.dkfz.de/en/research/dktk-researchers/siveke-groupGoogle:
"Jens Siveke"Parents
Sign in to add mentor| Alf Hamman | grad student | 1999 | University of Hamburg | |
| (Thesis: "T helper 1/2 cells: chemokine-induced chemotaxis and chemokine receptor expression,") | ||||
Children
Sign in to add trainee
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Mazur PK, Herner A, Mello SS, et al. (2024) Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nature Medicine |
| Hidalgo-Sastre A, Lubeseder-Martellato C, Engleitner T, et al. (2020) Mir34a constrains pancreatic carcinogenesis. Scientific Reports. 10: 9654 |
| Kaissis GA, Ziegelmayer S, Lohöfer FK, et al. (2020) Image-Based Molecular Phenotyping of Pancreatic Ductal Adenocarcinoma. Journal of Clinical Medicine. 9 |
| Walter K, Tiwary K, Trajkovic-Arsic M, et al. (2019) MEK Inhibition Targets Cancer Stem Cells and Impedes Migration of Pancreatic Cancer Cells and . Stem Cells International. 2019: 8475389 |
| Horak P, Heining C, Kreutzfeldt S, et al. (2019) Abstract 468: Clinical relevance of comprehensive genomic analysis in advanced-stage cancers and rare malignancies: Results from the MASTER trial of the German Cancer Consortium Cancer Research |
| Lee K, Bodoky G, Blanc J, et al. (2018) Decreased appetite (DA) at baseline impacts prognosis in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: v42-v43 |
| Lakatos G, Lee K, Siveke J, et al. (2018) Prognostic value of baseline biliary stents on outcomes in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the NAPOLI-1 trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: v42 |
| Mercadé TM, Wang-Gillam A, Chen L, et al. (2018) The effect of best response to prior anticancer therapy on efficacy outcomes in the NAPOLI-1 trial of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: v42 |
| Mercadé TM, Wang-Gillam A, Chen L, et al. (2018) Prognostic effect of primary tumor location in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: v41-v42 |
| Behrens D, Büttner B, Lawlor RL, et al. (2018) Abstract 4093: Preclinical evaluation of novel treatment strategies in patient-derived xenograft (PDX) models of pancreatic cancer Tumor Biology |